Changes and clinical significance of serum soluble Apo-1/Fas in pancreatic cancer.
- Author:
Qi-lian LIANG
1
;
Da-chao PAN
;
Zheng-min YIN
;
Guo-xun LIU
;
Qin YANG
;
Jie-rong XIE
;
You-wen FU
;
Liang-zhen CAI
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma, Mucinous; blood; drug therapy; Adult; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Carcinoma, Pancreatic Ductal; blood; drug therapy; Cisplatin; administration & dosage; Deoxycytidine; administration & dosage; analogs & derivatives; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; blood; drug therapy; Prognosis; Remission Induction; fas Receptor; blood
- From: Chinese Journal of Oncology 2006;28(3):214-216
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo detect changes of serum soluble Apo-1/Fas (sApo-1/Fas) in pancreatic cancer patients and to investigate its clinical value in assessing the effect of chemotherapy.
METHODSThe serum level of sApo-1/Fas in 30 normal control subjects and 58 pancreatic cancer patients were detected using enzyme-linked immunosorbent assay (ELISA), and the sApo-1/Fas level of 48 pancreatic cancer patients, before and after chemotherapy was compared.
RESULTSCompared with the level of the control group, the level of serum soluble Apo-1/Fas was significantly correlated with clinical stage but not with age, sex or pathologic type of pancreatic cancer. It was elevated gradually from stage II to IV (P < 0.01). However, it would obviously decrease in pancreatic cancer patients after chemotherapy (P < 0.01).
CONCLUSIONThe serum soluble Apo-1/Fas may be involved in the development of pancreatic cancer, and it may be used as one parameter to assess the disease status and prognosis of pancreatic cancer patient.
